We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

We've had our Eyes On some of the latest Pharmaceutical news including approvals, partnering, mergers, research programs, and

We've had our Eyes On recent data releases, commercial strategy updates, and some FDA updates. What caught your Eye last week?

This week we've had Eyes how BioPharma are bolstering their Portfolios for long-term success. From licensing assets ...

2024 is off to a busy start with M&A activities highlighted at the JP Morgan Healthcare Conference, plus another Genetic Medicines approval.